Emerging Field of Biased Opioid Agonists

References

1. • Bruchas M.R.
   • Roth B.L.
   New technologies for elucidating opioid receptor function.
   Trends Pharmacol Sci. 2016; 37: 279-289
   View in Article

   • Google Scholar
2. • DeWeerdt S.
   Tracing the US opioid crisis to its roots.
   Nature. 2019; 573: S10-S12
   View in Article

   • Google Scholar
3. • Michel M.C.
   • Charlton S.J.
   Biased agonism in drug discovery-is it too soon to choose a path?.
   Mol Pharmacol. 2018; 93: 259-265
   View in Article

   • Google Scholar
4. • Smith J.S.
   • Lefkowitz R.J.
   • Rajagopal S.
   Biased signaling: from simple switches to allosteric microprocessors.
   Nat Rev Drug Discov. 2018; 17: 243-260
   View in Article

   • Google Scholar
5. • Wingler L.M.
   • Lefkowitz R.J.
   Conformational basis of g protein-coupled receptor signaling versatility.
   Trends Cell Biol. 2020; 30: 736-747
   View in Article

   • Google Scholar
6. • Kenakin T.
   Biased receptor signaling in drug discovery.
   Pharmacol Rev. 2019; 71: 267-315
   View in Article

   • Google Scholar
7. • Onfroy L.
   • Galandrin S.
   • Pontier S.M.
   • et al.
   G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning.
   Sci Rep. 2017; 7: 7885
   View in Article

   • Google Scholar
8. • Goodman L.S.
   • Gilman A.
   The pharmacological basis of therapeutics: a textbook of pharmacology, toxicology, and therapeutics for physicians and medical students.
   1st ed. Macmillan Publishing, New York1941
   View in Article

   • Google Scholar
9. • Pert C.B.
   • Snyder S.H.
   Opiate receptor: demonstration in nervous tissue.
   Science. 1973; 179: 1011-1014
   View in Article

   • Google Scholar
10. • Gillis A.
    • Kliewer A.
    • Kelly E.
    • et al.
    Critical assessment of g protein-biased agonism at the μ-opioid receptor.
    Trends Pharmacol Sci. 2020; 41: 947-959
    View in Article

    • Google Scholar
11. • Siuda E.R.
    • Carr R.
    • Rominger D.H.
    • et al.
    Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics.
    Curr Opin Pharmacol. 2017; 32: 77-84
    View in Article

    • Google Scholar
12. • Che T.
    • Dwivedi-Agnihotri H.
    • Shukla A.K.
    • et al.
    Biased ligands at opioid receptors: Current status and future directions.
    Sci Signal. 2021; 14: eaav0320
    View in Article

    • Google Scholar
13. • Porter-Stransky K.A.
    • Weinshenker D.
    Arresting the development of addiction: the role of β -arrestin 2 in drug abuse.
    J Pharmacol Exp Ther. 2017; 361: 341-348
    View in Article

    • Google Scholar
14. • Bohn L.M.
    • Lefkowitz R.J.
    • Gainetdinov R.R.
    • et al.
    Enhanced morphine analgesia in mice lacking beta-arrestin 2.
    Science. 1999; 286: 2495-2498
    View in Article

    • Google Scholar
15. • Bohn L.M.
    • Gainetdinov R.R.
    • Lin F.T.
    • et al.
    Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.
    Nature. 2000; 408: 720-723
    View in Article

    • Google Scholar
16. • Raehal K.M.
    • Walker J.K.L.
    • Bohn L.M.
    Morphine side effects in beta-arrestin 2 knockout mice.
    J Pharmacol Exp Ther. 2005; 314: 1195-1201
    View in Article

    • Google Scholar
17. • Matthes H.W.
    • Smadja C.
    • Valverde O.
    • et al.
    Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.
    J Neurosci. 1998; 18: 7285-7295
    View in Article

    • Google Scholar
18. • Montandon G.
    • Slutsky A.S.
    Solving the opioid crisis: respiratory depression by opioids as critical end point.
    Chest. 2019; 156: 653-658
    View in Article

    • Google Scholar
19. • Varga A.G.
    • Reid B.T.
    • Kieffer B.L.
    • et al.
    Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice.
    J Physiol. 2020; 598: 189-205
    View in Article

    • Google Scholar
20. • Bachmutsky I.
    • Wei X.P.
    • Kish E.
    • et al.
    Opioids depress breathing through two small brainstem sites.
    Elife. 2020; 9: e52694
    View in Article

    • Google Scholar
21. • Levitt E.S.
    • Abdala A.P.
    • Paton J.F.R.
    • et al.
    Μ opioid receptor activation hyperpolarizes respiratory-controlling kölliker-fuse neurons and suppresses post-inspiratory drive.
    J Physiol. 2015; 593: 4453-4469
    View in Article

    • Google Scholar
22. • Kliewer A.
    • Gillis A.
    • Hill R.
    • et al.
    Morphine-induced respiratory depression is independent of β-arrestin2 signalling.
    Br J Pharmacol. 2020; 177: 2923-2931
    View in Article

    • Google Scholar
23. • Tan H.S.
    • Habib A.S.
    Oliceridine: a novel drug for the management of moderate to severe acute pain - a review of current evidence.
    J Pain Res. 2021; 14: 969-979
    View in Article

    • Google Scholar
24. • Chen X.T.
    • Pitis P.
    • Liu G.
    • et al.
    Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (Trv130), for the treatment of acute severe pain.
    J Med Chem. 2013; 56: 8019-8031
    View in Article

    • Google Scholar
25. Commissioner, O. FDA Approves New Opioid for Intravenous Use in Hospitals, Other Controlled Clinical Settings.
    (Available at:)
    https://www.fda.gov/news-events/press-announcements/fda-approves-newopioid- intravenous-use-hospitals-other-controlled-clinical-settings
    (Accessed 1 October 2022)
    View in Article

    • Google Scholar
26. • Pedersen M.F.
    • Wróbel T.M.
    • Märcher-Rørsted E.
    • et al.
    Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
    Neuropharmacology. 2020; 166: 107718
    View in Article

    • Google Scholar
27. • Liang D.Y.
    • Li W.W.
    • Nwaneshiudu C.
    • et al.
    Pharmacological characters of oliceridine, a μ-opioid receptor g-protein–biased ligand in mice.
    Anesth Analg. 2019; 129: 1414-1421
    View in Article

    • Google Scholar
28. • Altarifi A.A.
    • David B.
    • Muchhala K.H.
    • et al.
    Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (Oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.
    J Psychopharmacol. 2017; 31: 730-739
    View in Article

    • Google Scholar
29. • Viscusi E.R.
    • Skobieranda F.
    • Soergel D.G.
    • et al.
    APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (Trv130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy.
    J Pain Res. 2019; 12: 927-943
    View in Article

    • Google Scholar
30. • Singla N.K.
    • Skobieranda F.
    • Soergel D.G.
    • et al.
    Apollo-2: a randomized, placebo and active-controlled phase iii study investigating oliceridine (Trv130), a g protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty.
    Pain Pract. 2019; 19: 715-731
    View in Article

    • Google Scholar
31. • Singla N.
    • Minkowitz H.S.
    • Soergel D.G.
    • et al.
    A randomized, Phase IIb study investigating oliceridine (Trv130), a novel μ-receptor G-protein pathway selective (Μ-gps) modulator, for the management of moderate to severe acute pain following abdominoplasty.
    J Pain Res. 2017; 10: 2413-2424
    View in Article

    • Google Scholar
32. • Gillis A.
    • Gondin A.B.
    • Kliewer A.
    • et al.
    Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.
    Sci Signal. 2020; 13: eaaz3140
    View in Article

    • Google Scholar
33. • Aiyer R.
    • Gulati A.
    • Gungor S.
    • et al.
    Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies.
    Anesth Analg. 2018; 127: 529-538
    View in Article

    • Google Scholar
34. • Gudin J.
    • Fudin J.
    A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain.
    Pain Ther. 2020; 9: 41-54
    View in Article

    • Google Scholar
35. Olinvyk [package insert]. Trevena Inc, Chesterbrook, PA2020
    View in Article

    • Google Scholar
36. • Li A.H.
    • Schmiesing C.
    • Aggarwal A.K.
    Evidence for continuing buprenorphine in the perioperative period.
    Clin J Pain. 2020; 36: 764-774
    View in Article

    • Google Scholar
37. • DeWire S.M.
    • Yamashita D.S.
    • Rominger D.H.
    • et al.
    A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
    J Pharmacol Exp Ther. 2013; 344: 708-717
    View in Article

    • Google Scholar
38. • Nickolls S.A.
    • Waterfield A.
    • Williams R.E.
    • et al.
    Understanding the effect of different assay formats on agonist parameters: a study using the μ-opioid receptor.
    J Biomol Screen. 2011; 16: 706-716
    View in Article

    • Google Scholar
39. • Kelly E.
    Efficacy and ligand bias at the μ-opioid receptor.
    Br J Pharmacol. 2013; 169: 1430-1446
    View in Article

    • Google Scholar
40. • Vasudevan L.
    • Vandeputte M.
    • Deventer M.
    • et al.
    Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Biochem Pharmacol. 2020; 177: 113910
    View in Article

    • Google Scholar
41. • Zebala J.A.
    • Schuler A.D.
    • Kahn S.J.
    • et al.
    Desmetramadol is identified as a g-protein biased μ opioid receptor agonist.
    Front Pharmacol. 2019; 10: 1680
    View in Article

    • Google Scholar
42. • Miotto K.
    • Cho A.K.
    • Khalil M.A.
    • et al.
    Trends in tramadol: pharmacology, metabolism, and misuse.
    Anesth Analg. 2017; 124: 44-51
    View in Article

    • Google Scholar
43. • Bohn L.M.
    • Gainetdinov R.R.
    • Sotnikova T.D.
    • et al.
    Enhanced rewarding properties of morphine, but not cocaine, in beta(Arrestin)-2 knock-out mice.
    J Neurosci. 2003; 23: 10265-10273
    View in Article

    • Google Scholar
44. • Negus S.S.
    • Freeman K.B.
    Abuse potential of biased mu opioid receptor agonists.
    Trends Pharmacol Sci. 2018; 39: 916-919
    View in Article

    • Google Scholar
45. • Faouzi A.
    • Varga B.R.
    • Majumdar S.
    Biased opioid ligands.
    Molecules. 2020; 25: 4257
    View in Article

    • Google Scholar
46. • James I.E.
    • Skobieranda F.
    • Soergel D.G.
    • et al.
    A first-in-human clinical study with trv734, an orally bioavailable g-protein-biased ligand at the μ-opioid receptor.
    Clin Pharmacol Drug Dev. 2020; 9: 256-266
    View in Article

    • Google Scholar
47. • Kruegel A.C.
    • Gassaway M.M.
    • Kapoor A.
    • et al.
    Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators.
    J Am Chem Soc. 2016; 138: 6754-6764
    View in Article

    • Google Scholar
48. • Kelly E.
    • Conibear A.
    • Henderson G.
    Biased agonism: lessons from studies of opioid receptor agonists.
    Annu Rev Pharmacol Toxicol. 2023; 63: 491-515
    View in Article

    • Google Scholar
49. • Yudin Y.
    • Rohacs T.
    The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
    Br J Pharmacol. 2019; 176: 3110-3125
    View in Article

    • Google Scholar
50. • Kudla L.
    • Bugno R.
    • Skupio U.
    • et al.
    Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine.
    Br J Pharmacol. 2019; 176: 4434-4445
    View in Article

    • Google Scholar
51. • Litman R.S.
    • Pagán O.H.
    • Cicero T.J.
    Abuse-deterrent opioid formulations.
    Anesthesiology. 2018; 128: 1015-1026
    View in Article

    • Google Scholar
52. • Van Zee A.
    The promotion and marketing of oxycontin: commercial triumph, public health tragedy.
    Am J Public Health. 2009; 99: 221-227
    View in Article

    • Google Scholar
53. • Miyazaki T.
    • Choi I.Y.
    • Rubas W.
    • et al.
    Nktr-181: a novel mu-opioid analgesic with inherently low abuse potential.
    J Pharmacol Exp Ther. 2017; 363: 104-113
    View in Article

    • Google Scholar
54. • Ding H.
    • Czoty P.W.
    • Kiguchi N.
    • et al.
    A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
    Proc Natl Acad Sci U S A. 2016; 113: E5511-E5518
    View in Article

    • Google Scholar
55. • Pasternak G.W.
    Mu opioid pharmacology: 40 years to the promised land.
    Adv Pharmacol. 2018; 82: 261-291
    View in Article

    • Google Scholar
56. • Servick K.
    Safety benefits of ‘biased’ opioids scrutinized.
    Science. 2020; 367: 966
    View in Article

    • Google Scholar